Mural Oncology (MURA) Competitors $2.46 -0.02 (-0.81%) Closing price 04:00 PM EasternExtended Trading$2.46 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MURA vs. CYBN, RAPT, TLSA, ACOG, BDTX, DERM, KYTX, ACRS, BIOA, and IPHAShould you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Cybin (CYBN), Rapt Therapeutics (RAPT), Tiziana Life Sciences (TLSA), Alpha Cognition (ACOG), Black Diamond Therapeutics (BDTX), Journey Medical (DERM), Kyverna Therapeutics (KYTX), Aclaris Therapeutics (ACRS), BioAge Labs (BIOA), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. Mural Oncology vs. Its Competitors Cybin Rapt Therapeutics Tiziana Life Sciences Alpha Cognition Black Diamond Therapeutics Journey Medical Kyverna Therapeutics Aclaris Therapeutics BioAge Labs Innate Pharma Cybin (NYSE:CYBN) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Do analysts rate CYBN or MURA? Cybin currently has a consensus price target of $85.00, indicating a potential upside of 957.21%. Mural Oncology has a consensus price target of $12.00, indicating a potential upside of 387.80%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Mural Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is CYBN or MURA more profitable? Cybin's return on equity of -37.58% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Mural Oncology N/A -83.39%-70.70% Which has stronger earnings and valuation, CYBN or MURA? Cybin is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$3.88-2.07Mural OncologyN/AN/A-$128.51M-$7.67-0.32 Do institutionals and insiders believe in CYBN or MURA? 17.9% of Cybin shares are held by institutional investors. Comparatively, 80.2% of Mural Oncology shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 2.2% of Mural Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor CYBN or MURA? In the previous week, Mural Oncology had 5 more articles in the media than Cybin. MarketBeat recorded 5 mentions for Mural Oncology and 0 mentions for Cybin. Cybin's average media sentiment score of 0.50 beat Mural Oncology's score of -0.24 indicating that Cybin is being referred to more favorably in the media. Company Overall Sentiment Cybin Positive Mural Oncology Neutral Which has more volatility & risk, CYBN or MURA? Cybin has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. SummaryCybin beats Mural Oncology on 10 of the 14 factors compared between the two stocks. Get Mural Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MURA vs. The Competition Export to ExcelMetricMural OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.83M$2.52B$5.70B$9.48BDividend YieldN/A1.76%4.59%3.99%P/E Ratio-0.329.1227.9019.95Price / SalesN/A746.51442.19102.72Price / CashN/A166.2336.5558.97Price / Book0.305.228.635.90Net Income-$128.51M$30.99M$3.24B$258.42M7 Day Performance-1.20%4.29%3.22%1.94%1 Month Performance0.82%13.40%10.72%12.02%1 Year Performance-28.28%0.59%34.94%20.81% Mural Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MURAMural Oncology3.2609 of 5 stars$2.46-0.8%$12.00+387.8%-28.1%$42.83MN/A-0.32119News CoverageCYBNCybin2.7446 of 5 stars$7.38-1.3%$85.00+1,052.5%N/A$171.53MN/A-1.7050RAPTRapt Therapeutics4.3256 of 5 stars$10.30+18.1%$19.80+92.3%-42.9%$171.27M$1.53M-0.5480News CoverageAnalyst UpgradeHigh Trading VolumeTLSATiziana Life Sciences1.2141 of 5 stars$1.45-2.4%N/A+97.8%$168.85MN/A0.008ACOGAlpha Cognition1.1348 of 5 stars$10.47-0.6%$20.00+91.0%N/A$167.73M$2.93M-8.72N/APositive NewsBDTXBlack Diamond Therapeutics2.2165 of 5 stars$2.93-0.5%$12.80+337.6%-48.6%$166.88MN/A48.9290DERMJourney Medical1.0447 of 5 stars$7.13-3.8%$9.50+33.2%+36.6%$166.71M$56.13M-18.3590Positive NewsKYTXKyverna Therapeutics1.9695 of 5 stars$3.83-13.0%$18.50+383.0%-54.0%$165.75M$7.03M-1.1396Positive NewsACRSAclaris Therapeutics1.7182 of 5 stars$1.53-3.5%$8.71+471.4%+20.0%$165.13M$18.72M-1.10100BIOABioAge LabsN/A$4.49-3.0%N/AN/A$160.97MN/A0.00N/AIPHAInnate Pharma1.9102 of 5 stars$1.76+3.2%$11.00+526.8%-10.9%$160.39M$21.77M0.00220Positive News Related Companies and Tools Related Companies Cybin Competitors Rapt Therapeutics Competitors Tiziana Life Sciences Competitors Alpha Cognition Competitors Black Diamond Therapeutics Competitors Journey Medical Competitors Kyverna Therapeutics Competitors Aclaris Therapeutics Competitors BioAge Labs Competitors Innate Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MURA) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MURA Stock Alerts